JPRN-UMIN000009739已完成2 期
biweekly irinotecan monotherapy for refractory advanced pancreatic cancer - biweekly irinotecan monotherapy for refractory advanced pancreatic cancer
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 53
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Patients with active infection 2) Patients with active GI bleeding 3) Patients with intestinal pneumonia, pulmonary fibrosis, and severe pulmonary emphysema 4) Patients with uncontrolled pleural effusion or ascites 5) Patients with watery diarrhea or ileus 6) Patients with synchronous or metachronous concomitant malignancies 7) Pregnant or lactating female or patients who are considering pregnancy 8) Patients with contraindication to irinotecan 9) Patients who are actively on other anticancer treatment 10) Inappropriate patients for entry on this study in the judgement of the investigator
研究者
相似试验
进行中（未招募）
1 期
Full dose S1 compared to reduced dose S-1/oxaliplatin. First-line treatment for older patients with metastic colorectal cancer.Treatment of older (= 70 years) patients with metastatic colorectal cancerMedDRA version: 17.1Level: PTClassification code 10052358Term: Colorectal cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-000394-39-FIOdense University Hospital160
进行中（未招募）
1 期
Clinical study of irinotecan weekly in patients with locally advanced or metastatic HER2-negative breast cancer and increased cancer cell copy number of the topoisomerase 1 gene”MedDRA version: 17.1Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 100000004864Metastatic breast cancerEUCTR2012-002348-26-DKDanish Breast Cancer Group (BDCG)40
进行中（未招募）
不适用
Phase II study of irinotecan weekly in combination with trastuzumab in patientswith locally advanced or metastatic HER2-positive breast cancer and increased cancer cell copy number of TOP1”Metastatic breast cancerEUCTR2012-002347-23-DKDanish Breast Cancer Group (DBCG)
已完成
1 期
Phase II Clinical Trial of Monotherapy with Irinotecan Hydrochloride (CPT-11) for Advanced or Recurrent Endometrial CancerAdvanced or recurrent endometrial cancerJPRN-UMIN000017079Kurume University26
进行中（未招募）
1 期
Medical treatment for patients with cancer of the esophagus or stomachPatients with esophagus or gastric cancer and who are platinum resistant and non-resectabelMedDRA version: 14.1Level: PTClassification code 10017758Term: Gastric cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-002321-30-DKOdense University Hospital